| Symbol | ZNTL |
|---|---|
| Name | ZENTALIS PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 10275 SCIENCE CENTER DRIVE,SUITE 200, SAN DIEGO, California, 92121, United States |
| Telephone | +1 858 - 263-4333 |
| Fax | — |
| — | |
| Website | https://www.zentalis.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001725160 |
| Description | Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer. Additional info from NASDAQ: |
2026-08-17 20:01
Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Read more
2026-08-14 17:15
New Form 424B5 - Zentalis Pharmaceuticals, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001628280-26-057108 <b>Size:</b> 573 KB
Read more
2026-08-14 02:23
Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering
Read more
2026-08-13 20:12
New Form SCHEDULE 13G/A - Zentalis Pharmaceuticals, Inc. <b>Filed:</b> 2026-08-13 <b>AccNo:</b> 0000312069-26-000217 <b>Size:</b> 6 KB
Read more
2026-08-13 17:14
New Form 424B5 - Zentalis Pharmaceuticals, Inc. <b>Filed:</b> 2026-08-13 <b>AccNo:</b> 0001628280-26-056729 <b>Size:</b> 603 KB
Read more
2026-08-03 21:00
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read more
2026-07-17 20:15
Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026
Read more
2026-06-01 21:00
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read more
2026-05-27 20:11
Director Campbell Shannon 🟢 acquired 114.2K shares of Zentalis Pharmaceuticals, Inc. (ZNTL) Transaction Date: May 26, 2026 | Filing ID: 000005
Read more
2026-05-27 20:07
(99% Neutral) ZENTALIS PHARMACEUTICALS, INC. (ZNTL) Announces New Board Appointment
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07546500 | A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Sub… | Phase3 | Ovarian Cancer | Recruiting | 2026-04-17 | 2030-04-30 | ClinicalTrials.gov |
| NCT06369155 | Azenosertib in Uterine Serous Carcinoma: Biomarker Study | Phase2 | Uterine Serous Carcinoma | Recruiting | 2025-03-05 | 2028-01-31 | ClinicalTrials.gov |
| NCT06015659 | ZN-c3 + Gemcitabine in Pancreatic Cancer | Phase2 | Advanced Pancreatic Adenocarcinoma | Active_Not_Recruiting | 2023-11-16 | 2027-06-01 | ClinicalTrials.gov |
| NCT05743036 | ZN-c3 in Adult Participants With Metastatic Colorectal Cancer | Phase1 | Metastatic Colorectal Cancer | Terminated | 2023-02-27 | 2025-07-09 | ClinicalTrials.gov |
| NCT05431582 | Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Ampl… | Phase1 | Tumors | Withdrawn | 2022-12-14 | 2022-12-14 | ClinicalTrials.gov |
| NCT05682170 | Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML) | Phase1 | Acute Myeloid Leukemia (AML) | Terminated | 2022-12-01 | 2024-07-26 | ClinicalTrials.gov |
| NCT05128825 | A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade S… | Phase2 | High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | Recruiting | 2022-02-17 | 2027-06-30 | ClinicalTrials.gov |
| NCT05198804 | A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistan… | Phase1 | Ovarian Cancer | Completed | 2022-01-27 | 2026-01-19 | ClinicalTrials.gov |
| NCT05199337 | Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chai… | Phase1 | Amyloidosis | Completed | 2021-11-30 | 2024-02-14 | ClinicalTrials.gov |
| NCT04833582 | A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With… | Phase1 | Osteosarcoma | Completed | 2021-08-01 | 2024-03-30 | ClinicalTrials.gov |
| NCT04814108 | A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Se… | Phase2 | Uterine Serous Carcinoma | Completed | 2021-07-28 | 2025-10-22 | ClinicalTrials.gov |
| NCT04854174 | A Food Effect Study of ZN-d5 in Healthy Female Volunteers | Phase1 | Healthy Volunteers | Completed | 2021-06-13 | 2021-07-05 | ClinicalTrials.gov |
| NCT04516447 | A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer | Phase1 | Solid Tumor | Recruiting | 2020-10-26 | 2028-06-30 | ClinicalTrials.gov |
| NCT04500587 | Phase 1 First in Human Study of ZN-d5 as a Single Agent | Phase1 | Acute Myeloid Leukemia | Completed | 2020-10-13 | 2023-12-12 | ClinicalTrials.gov |
| NCT04158336 | A Study of Azenosertib (ZN-c3) in Participants With Solid Tumors | Phase1 | Solid Tumor | Completed | 2019-11-01 | 2025-05-06 | ClinicalTrials.gov |
Total clinical trials: 15
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Azenosertib | Other | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07546500 |
| Investigator's choice of Chemotherapy | Drug | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07546500 |
| Azenosertib | Other | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07546500 |
| Investigator's choice of Chemotherapy | Drug | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07546500 |
| azenosertib | Other | Phase PHASE2 | High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | RECRUITING | NCT05128825 |
| Azenosertib | Other | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07546500 |
| Investigator's choice of Chemotherapy | Drug | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07546500 |
| Azenosertib | Other | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07546500 |
| Investigator's choice of Chemotherapy | Drug | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07546500 |
| Azenosertib | Other | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07546500 |
| Investigator's choice of Chemotherapy | Drug | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07546500 |
| Azenosertib | Other | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07546500 |
| Investigator's choice of Chemotherapy | Drug | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07546500 |
| Azenosertib | Other | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07546500 |
| Investigator's choice of Chemotherapy | Drug | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07546500 |
| Azenosertib | Other | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07546500 |
| Investigator's choice of Chemotherapy | Drug | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07546500 |
| Azenosertib | Other | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07546500 |
| Investigator's choice of Chemotherapy | Drug | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07546500 |
| Azenosertib | Other | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07546500 |
| Investigator's choice of Chemotherapy | Drug | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07546500 |
| Azenosertib | Other | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07546500 |
| Investigator's choice of Chemotherapy | Drug | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07546500 |
| Azenosertib | Other | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07546500 |
| Investigator's choice of Chemotherapy | Drug | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07546500 |
| Azenosertib | Other | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07546500 |
| Investigator's choice of Chemotherapy | Drug | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07546500 |
| Azenosertib | Other | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07546500 |
| Investigator's choice of Chemotherapy | Drug | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07546500 |
| Azenosertib | Other | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07546500 |
| Investigator's choice of Chemotherapy | Drug | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07546500 |
| Azenosertib | Other | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07546500 |
| Investigator's choice of Chemotherapy | Drug | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07546500 |
| Azenosertib | Other | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07546500 |
| Investigator's choice of Chemotherapy | Drug | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07546500 |
| Azenosertib | Other | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07546500 |
| Investigator's choice of Chemotherapy | Drug | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07546500 |
| Azenosertib | Other | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07546500 |
| Investigator's choice of Chemotherapy | Drug | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07546500 |
| Gemzar | Other | Phase PHASE2 | Advanced Pancreatic Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06015659 |
| Zentalis | Other | Phase PHASE2 | Advanced Pancreatic Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06015659 |
| Gemzar | Other | Phase PHASE2 | Advanced Pancreatic Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06015659 |
| Zentalis | Other | Phase PHASE2 | Advanced Pancreatic Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06015659 |
| Gemzar | Other | Phase PHASE2 | Advanced Pancreatic Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06015659 |
| Zentalis | Other | Phase PHASE2 | Advanced Pancreatic Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06015659 |
| Gemzar | Other | Phase PHASE2 | Advanced Pancreatic Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06015659 |
| Zentalis | Other | Phase PHASE2 | Advanced Pancreatic Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06015659 |
| Gemzar | Other | Phase PHASE2 | Advanced Pancreatic Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06015659 |
| Zentalis | Other | Phase PHASE2 | Advanced Pancreatic Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06015659 |
| Gemzar | Other | Phase PHASE2 | Advanced Pancreatic Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06015659 |
| Zentalis | Other | Phase PHASE2 | Advanced Pancreatic Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06015659 |
| Gemzar | Other | Phase PHASE2 | Advanced Pancreatic Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06015659 |
| Zentalis | Other | Phase PHASE2 | Advanced Pancreatic Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06015659 |
| Gemzar | Other | Phase PHASE2 | Advanced Pancreatic Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06015659 |
| Zentalis | Other | Phase PHASE2 | Advanced Pancreatic Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06015659 |
| Gemzar | Other | Phase PHASE2 | Advanced Pancreatic Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06015659 |
| Zentalis | Other | Phase PHASE2 | Advanced Pancreatic Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06015659 |
| Gemzar | Other | Phase PHASE2 | Advanced Pancreatic Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06015659 |
| Zentalis | Other | Phase PHASE2 | Advanced Pancreatic Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06015659 |
| Gemzar | Other | Phase PHASE2 | Advanced Pancreatic Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06015659 |
| Zentalis | Other | Phase PHASE2 | Advanced Pancreatic Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06015659 |
| Pembrolizumab | Other | Phase PHASE1 | Tumors | WITHDRAWN | NCT05431582 |
| Bevacizumab | Other | Phase PHASE1 | Tumors | WITHDRAWN | NCT05431582 |
| ZN-c3 | Other | Phase PHASE1 | Tumors | WITHDRAWN | NCT05431582 |
| ZN-c3 | Other | Phase PHASE1 | Acute Myeloid Leukemia (AML) | TERMINATED | NCT05682170 |
| ZN-d5 ZN-c3 | Other | Phase PHASE1 | Acute Myeloid Leukemia (AML) | TERMINATED | NCT05682170 |
| ZN-c3 | Other | Phase PHASE1 | Acute Myeloid Leukemia (AML) | TERMINATED | NCT05682170 |
| ZN-d5 ZN-c3 | Other | Phase PHASE1 | Acute Myeloid Leukemia (AML) | TERMINATED | NCT05682170 |
| ZN-d5 | Other | Phase PHASE1 | Amyloidosis | COMPLETED | NCT05199337 |
| ZN-d5 | Other | Phase PHASE1 | Amyloidosis | COMPLETED | NCT05199337 |
| ZN-d5 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04854174 |
| ZN-d5 | Other | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT04500587 |
| ZN-d5 | Other | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT04500587 |
| ZN-d5 | Other | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT04500587 |
| Cetuximab | Other | Phase PHASE1 | Metastatic Colorectal Cancer | TERMINATED | NCT05743036 |
| Encorafenib | Other | Phase PHASE1 | Metastatic Colorectal Cancer | TERMINATED | NCT05743036 |
| ZN-c3 | Other | Phase PHASE1 | Metastatic Colorectal Cancer | TERMINATED | NCT05743036 |
| Cetuximab | Other | Phase PHASE1 | Metastatic Colorectal Cancer | TERMINATED | NCT05743036 |
| Encorafenib | Other | Phase PHASE1 | Metastatic Colorectal Cancer | TERMINATED | NCT05743036 |
| ZN-c3 | Other | Phase PHASE1 | Metastatic Colorectal Cancer | TERMINATED | NCT05743036 |
| Pembrolizumab | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06351332 |
| Carboplatin | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06351332 |
| Azenosertib | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06351332 |
| Gemzar | Other | Phase PHASE2 | Advanced Pancreatic Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06015659 |
| Zentalis | Other | Phase PHASE2 | Advanced Pancreatic Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06015659 |
| Azenosertib | Other | Phase PHASE2 | Uterine Serous Carcinoma | RECRUITING | NCT06369155 |
| Niraparib | Other | Phase PHASE1 | Ovarian Cancer | COMPLETED | NCT05198804 |
| Azenosertib | Other | Phase PHASE1 | Ovarian Cancer | COMPLETED | NCT05198804 |
| Niraparib | Other | Phase PHASE1 | Ovarian Cancer | COMPLETED | NCT05198804 |
| Azenosertib | Other | Phase PHASE1 | Ovarian Cancer | COMPLETED | NCT05198804 |
| Niraparib | Other | Phase PHASE1 | Ovarian Cancer | COMPLETED | NCT05198804 |
| Azenosertib | Other | Phase PHASE1 | Ovarian Cancer | COMPLETED | NCT05198804 |
| Azenosertib | Other | Phase PHASE2 | Uterine Serous Carcinoma | COMPLETED | NCT04814108 |
| Azenosertib | Other | Phase PHASE2 | Uterine Serous Carcinoma | COMPLETED | NCT04814108 |
| Azenosertib | Other | Phase PHASE1 | Solid Tumor | COMPLETED | NCT04158336 |
| Azenosertib | Other | Phase PHASE1 | Solid Tumor | COMPLETED | NCT04158336 |
| Azenosertib | Other | Phase PHASE1 | Solid Tumor | COMPLETED | NCT04158336 |
| Gemcitabine | Other | Phase PHASE1 | Osteosarcoma | COMPLETED | NCT04833582 |
| Azenosertib | Other | Phase PHASE1 | Osteosarcoma | COMPLETED | NCT04833582 |
| Gemcitabine | Other | Phase PHASE1 | Osteosarcoma | COMPLETED | NCT04833582 |
| Azenosertib | Other | Phase PHASE1 | Osteosarcoma | COMPLETED | NCT04833582 |
| Bevacizumab | Other | Phase PHASE1 | Solid Tumor | RECRUITING | NCT04516447 |
| Gemcitabine | Other | Phase PHASE1 | Solid Tumor | RECRUITING | NCT04516447 |
| Paclitaxel | Other | Phase PHASE1 | Solid Tumor | RECRUITING | NCT04516447 |
| Pegylated liposomal doxorubicin | Other | Phase PHASE1 | Solid Tumor | RECRUITING | NCT04516447 |
| Carboplatin | Other | Phase PHASE1 | Solid Tumor | RECRUITING | NCT04516447 |
| Azenosertib | Other | Phase PHASE1 | Solid Tumor | RECRUITING | NCT04516447 |
| Bevacizumab | Other | Phase PHASE1 | Solid Tumor | RECRUITING | NCT04516447 |
| Gemcitabine | Other | Phase PHASE1 | Solid Tumor | RECRUITING | NCT04516447 |
| Paclitaxel | Other | Phase PHASE1 | Solid Tumor | RECRUITING | NCT04516447 |
| Pegylated liposomal doxorubicin | Other | Phase PHASE1 | Solid Tumor | RECRUITING | NCT04516447 |
| Carboplatin | Other | Phase PHASE1 | Solid Tumor | RECRUITING | NCT04516447 |
| Azenosertib | Other | Phase PHASE1 | Solid Tumor | RECRUITING | NCT04516447 |
| azenosertib | Other | Phase PHASE2 | High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | RECRUITING | NCT05128825 |
| azenosertib | Other | Phase PHASE2 | High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | RECRUITING | NCT05128825 |
| azenosertib | Other | Phase PHASE2 | High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | RECRUITING | NCT05128825 |
| Azenosertib | Other | Phase PHASE3 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07546500 |
| Investigator's choice of Chemotherapy | Drug | Phase PHASE3 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07546500 |
| Azenosertib | Other | Phase PHASE3 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07546500 |
| Investigator's choice of Chemotherapy | Drug | Phase PHASE3 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07546500 |
| Azenosertib | Other | Phase PHASE3 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07546500 |
| Investigator's choice of Chemotherapy | Drug | Phase PHASE3 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07546500 |
| azenosertib | Other | Phase PHASE2 | High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | RECRUITING | NCT05128825 |
| azenosertib | Other | Phase PHASE2 | High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | RECRUITING | NCT05128825 |
| azenosertib | Other | Phase PHASE2 | High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | RECRUITING | NCT05128825 |
| azenosertib | Other | Phase PHASE2 | High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | RECRUITING | NCT05128825 |
| azenosertib | Other | Phase PHASE2 | High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | RECRUITING | NCT05128825 |
| azenosertib | Other | Phase PHASE2 | High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | RECRUITING | NCT05128825 |
| azenosertib | Other | Phase PHASE2 | High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | RECRUITING | NCT05128825 |
| azenosertib | Other | Phase PHASE2 | High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | RECRUITING | NCT05128825 |
| azenosertib | Other | Phase PHASE2 | High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | RECRUITING | NCT05128825 |
| azenosertib | Other | Phase PHASE2 | High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | RECRUITING | NCT05128825 |
| azenosertib | Other | Phase PHASE2 | High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | RECRUITING | NCT05128825 |
| azenosertib | Other | Phase PHASE2 | High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | RECRUITING | NCT05128825 |
| Azenosertib | Other | Phase PHASE3 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07546500 |
| Investigator's choice of Chemotherapy | Drug | Phase PHASE3 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07546500 |
| Azenosertib | Other | Phase PHASE3 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07546500 |
| Investigator's choice of Chemotherapy | Drug | Phase PHASE3 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07546500 |
| Azenosertib | Other | Phase PHASE3 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07546500 |
| Investigator's choice of Chemotherapy | Drug | Phase PHASE3 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07546500 |
| Azenosertib | Other | Phase PHASE3 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07546500 |
| Investigator's choice of Chemotherapy | Drug | Phase PHASE3 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07546500 |
| Azenosertib | Other | Phase PHASE3 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07546500 |
| Investigator's choice of Chemotherapy | Drug | Phase PHASE3 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07546500 |
| Azenosertib | Other | Phase PHASE3 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07546500 |
| Investigator's choice of Chemotherapy | Drug | Phase PHASE3 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07546500 |
| Azenosertib | Other | Phase PHASE3 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07546500 |
| Investigator's choice of Chemotherapy | Drug | Phase PHASE3 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07546500 |
| Azenosertib | Other | Phase PHASE3 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07546500 |
| Investigator's choice of Chemotherapy | Drug | Phase PHASE3 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07546500 |
| Niraparib | DRUG | Phase PHASE1 | Ovarian Cancer | COMPLETED | NCT05198804 |
| Azenosertib | DRUG | Phase PHASE1 | Ovarian Cancer | COMPLETED | NCT05198804 |
| ZN-d5 ZN-c3 | DRUG | Phase PHASE1 | Acute Myeloid Leukemia (AML) | TERMINATED | NCT05682170 |
| ZN-d5 | DRUG | Phase PHASE1 | Amyloidosis | COMPLETED | NCT05199337 |
| Cetuximab | DRUG | Phase PHASE1 | Metastatic Colorectal Cancer | TERMINATED | NCT05743036 |
| Encorafenib | DRUG | Phase PHASE1 | Metastatic Colorectal Cancer | TERMINATED | NCT05743036 |
| Gemzar | DRUG | Phase PHASE2 | Advanced Pancreatic Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06015659 |
| Zentalis | DRUG | Phase PHASE2 | Advanced Pancreatic Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06015659 |
| azenosertib | DRUG | Phase PHASE2 | High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | RECRUITING | NCT05128825 |
| Gemcitabine | DRUG | Phase PHASE1 | Osteosarcoma | COMPLETED | NCT04833582 |
| Paclitaxel | DRUG | Phase PHASE1 | Solid Tumor | RECRUITING | NCT04516447 |
| Pegylated liposomal doxorubicin | DRUG | Phase PHASE1 | Solid Tumor | RECRUITING | NCT04516447 |
| Carboplatin | DRUG | Phase PHASE1 | Solid Tumor | RECRUITING | NCT04516447 |
| Azenosertib | DRUG | Phase PHASE2 | Uterine Serous Carcinoma | COMPLETED | NCT04814108 |
| Bevacizumab | BIOLOGICAL | Phase PHASE1 | Solid Tumor | RECRUITING | NCT04516447 |
| ZN-c3 | DRUG | Phase PHASE1 | Acute Myeloid Leukemia (AML) | TERMINATED | NCT05682170 |
Total products: 166